WO2004007471A1 - N−フェニル−(2r,5s)ジメチルピペラジン誘導体 - Google Patents
N−フェニル−(2r,5s)ジメチルピペラジン誘導体 Download PDFInfo
- Publication number
- WO2004007471A1 WO2004007471A1 PCT/JP2003/008860 JP0308860W WO2004007471A1 WO 2004007471 A1 WO2004007471 A1 WO 2004007471A1 JP 0308860 W JP0308860 W JP 0308860W WO 2004007471 A1 WO2004007471 A1 WO 2004007471A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lower alkyl
- phenyl
- dimethylpiperazine
- substituted
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
Definitions
- the present invention relates to novel N-phenyl- (2R, 5S) dimethylpiperazine derivatives and their salts, medicaments, and intermediates, which are useful as medicaments, particularly as antiandrogens.
- Androgens a type of steroid hormone, are secreted from the testes and the adrenal cortex, causing androgenic effects.
- the androgen is taken into target cells and acts on the androgen receptor, and the androgen-bound receptor forms a dimer.
- the dimer binds to the androgen-response element on DNA, promotes the synthesis of m-RNA, and induces various functions in vivo by inducing proteins that control androgen action ( Prostate Suppl., 6, 1996, 45-51, Trends in Endocrinology and Metabolism, 1998, 9 (8), 317-324).
- Non-Patent Document 1 acyluanilide derivatives such as flutamide (Patent Document 1) and bicalutamide (Patent Documents 2 and 3) are known, but they do not have sufficient anti-androgenic activity. Therefore, in the treatment of prostate cancer, combination therapy with LH-RH agonist is generally used (Non-Patent Document 1).
- the compound of the present invention has the following general formula in the claims of Patent Document 4.
- N-phenyl-1- (2R, 5S) represented by the following general formula (I)
- Dimethyl piperazine derivatives that is, a compound not specifically disclosed in Patent Document 4
- a novel N-phenyl- (2R, 5S) dimethylpiperazine derivative which is a compound 3-substituted on a phenyl group
- the present invention has an excellent effect of reducing the size of the prostate gland without exhibiting a weight-reducing effect, thereby completing the present invention.
- the compound of the present invention has no specific disclosure in the above-mentioned literatures based on Examples and the like.
- the compound of the present invention exhibits good pharmacokinetics, and thus has an excellent prostate reduction effect that cannot be expected from in vitro activity. What was shown was unexpected.
- An object of the present invention is to provide a novel N-phenyl (2R, 5S) dimethylpiperazine derivative and a salt thereof, which are useful as a medicine, especially as an antiandrogen.
- the present invention relates to an N-phenyl (2R, 5S) dimethylpyrazine derivative or a salt thereof shown in the following (1) to (4).
- R 1 Cl, F, Br, -CN, -CH 3 , -CF 3 , or -0-lower alkyl
- R 2 H, F, or -OCH 3
- R 3 H or lower alkyl
- Cy a group represented by the following groups a) to e)
- R 1 is Cl, F, Br, CN, --CH3, or - O-lower alkyl, and wherein R 3 is H
- (5) to (8) relate to pharmaceutical uses and treatment methods of N-phenyl (2R, 5S) dimethylpiperazine derivatives.
- a pharmaceutical composition comprising, as an active ingredient, the N-phenyl (2R, 5S) dimethylpiperazine derivative or the pharmaceutically acceptable salt thereof according to (1).
- a therapeutic agent for prostate cancer comprising a therapeutically effective amount of the N-phenyl (2R, 5S) dimethylpiperazine derivative or a pharmaceutically acceptable salt thereof according to (1) as an active ingredient.
- the present invention relates to an intermediate useful for producing the N-phenyl (2R, 5S) dimethylpiperazine derivative of the present invention.
- (9) A compound represented by the following general formula (Ufa) or a salt thereof.
- R 3 H or lower alkyl
- X is F Br -CN, or - when the CF 3
- R lower alkyl, halogeno lower alkyl, phenyl optionally substituted with nitro, or succinimide optionally substituted with OH
- lower alkyl is a C M alkyl, preferably methyl, Echiru, propyl Le, isopropyl, C Bok 4 alkyl, such as tert- butyl, more preferably C Bok 3 ⁇ alkyl.
- Halogen includes, for example, fluorine, chlorine, bromine or iodine atom.
- halogeno lower alkyl is a group in which an arbitrary hydrogen atom of the above-mentioned lower alkyl is substituted by the above-mentioned halogen, and preferably includes trifluoromethyl, 22, 2-trifluoroethyl and the like.
- Cycloalkyl means cycloalkyl having 3 to 8 carbon atoms, and specifically includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like. Preferably, it is a cycloalkyl having 3 to 6 carbon atoms.
- Aryl means an aromatic hydrocarbon ring having 6 to 10 carbon atoms, specifically, benzene and naphthalene.
- Cy is preferably a pyridin-3-yl group in which the 6-position of the pyridine ring is substituted with -CN, -CF3, or halogen.
- the following method is preferred.
- R 1 CK F, Br, -CN, -CH 3 , -CF 3 , or -O-lower alkyl
- R 2 H, F, or —OCH 3
- R 3 H or lower alkyl
- Cy a group represented by the following groups a) to e)
- Benzopyrazine (optionally substituted with lower alkyl or cycloalkyl), quinoxaline (optionally substituted with -0-lower alkyl or morpholiel) I (may be substituted by lower alkyl or morpholinyl)
- the above production method comprises the steps of: preparing an optically active starting compound represented by the general formula (II);
- the compound (I) of the present invention which has few side effects and an excellent effect of reducing prostate and has excellent oral activity, can be obtained.
- Examples of the reactive derivative of the compound (III) include methyl carbamic acid, alkyl esters such as ethyl ester, isobutyl ester and tert-butyl ester, trifluoromethyl ester, and 2,2,2-trifluoroethyl ester.
- Phenyl esters such as halogeno lower alkyl esters, phenyl esters, p-nitrophenyl esters, 2,4-dinitrophenyl esters, and N-hydroxyamines such as 1-hydroxysuccinimide and 1-hydroxybenzotriazole.
- Active esters of carbamic acid derived from alcohols with good elimination properties such as carbamic acid chloride, carbamic acid halides such as carbamic acid bromide, carbamic acid azide, symmetric acid anhydrides, alkyl carbonate halides, etc.
- Halocarboxylic acid al Mixed acid anhydrides obtained by reacting with organic esters such as triesters and bivaloyl halides, and mixed acids based on phosphoric acids obtained by combining organic phosphorus compounds such as triphenylphosphine with activators such as N-promosuccinimide.
- Mixed acid anhydrides such as anhydrides and isocyanates can be mentioned.
- the compound (I) of the present invention has geometric isomers based on amide bonds. Depending on the type of substituent Depending on the case, it may have one or more asymmetric centers such as carbon, nitrogen, sulfur, etc. and axial asymmetry. Based on this, optical isomers such as (R) -form, (S) -form, racemic , Diastereomers, etc. exist. Further, depending on the type of the substituent, the compound has a double bond, and there are geometrical isomers such as a (Z) -form, an (E) -form, and a cis-form and a trans-form based on a ring such as cyclohexane. . The present invention includes all separated or mixed forms of these isomers.
- the compound of the present invention forms a salt.
- an acid addition salt with an inorganic acid or an organic acid, or a salt with an inorganic or organic base, and a pharmaceutically acceptable salt is preferred.
- mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid, or formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid
- Addition salts with organic acids such as lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid or toluenesulfonic acid, or acidic amino acids such as aspartic acid or glutamic acid, sodium, potassium, Inorganic bases such as magnesium, magnesium / aluminum, aluminum, and lithium; organic bases such as methylamine, ethylamine, and ethanolamine
- the quaternary ammonium salt is specifically a lower alkyl halide, a lower alkyl triflate, a lower alkyl tosylate or a benzyl octylide, and is preferably a methyl oxide or a benzyl chloride.
- the compound of the present invention may form a solvate such as a hydrate and an ethanol solvate, and some compounds may have a polymorph, and all of them are included.
- the compound of the present invention also includes a pharmacologically acceptable prodrug.
- a pharmacologically acceptable prodrug of the compound of the present invention include the group described in Prog. Med. 5: 2157-2161 (1985) and the group described in Hirokawa Shoten, 1990 Development of Vol. 7 Molecular Design 16 16 to 198 p. Specifically, it is a group which can be converted to the primary amine or secondary amine of the present invention, ⁇ H, CO OH, or the like by hydrolysis, solvolysis or under physiological conditions.
- prodrug of the group examples include mono-OC (O) mono-substituted lower alkyl mono-C (O) OR (R represents H or lower alkyl, the same applies hereinafter), -OC ( ⁇ ) mono-substituted Lower alkenylene which may be substituted C (O) ⁇ R, -OC ( ⁇ ) aryl which may be monosubstituted, — OC ( ⁇ ) lower alkylalkyl ⁇ _lower alkyl-1-C ( ⁇ ) OR, -OC (O) one C ( ⁇ ) R,-OC (O) Optionally substituted lower alkyl, 100 SO 2 —optionally substituted lower alkyl-1 C (0) OR, 110-fluoridyl, 5-methyl-1,3-dioxolene-2-one-4 Illuminomethyloxy and the like.
- the compound (I) of the present invention and a pharmaceutically acceptable salt thereof are useful for prostate cancer, prostatic hyperplasia, masculosis, hirsutism, baldness, in which androgen is an aggravating factor based on excellent anti-androgen activity and oral activity.
- androgen is an aggravating factor based on excellent anti-androgen activity and oral activity.
- diseases such as sickness, acne and seborrhea.
- a substituted amine represented by the general formula (II) or a salt thereof is reacted with a compound represented by the general formula (III) or a reactive derivative thereof.
- This is a method for producing the compound (I) of the present invention.
- a condensation reaction with an isocyanate, an alkyl ester of carbamic acid, a halogeno lower alkyl ester, a phenyl ester and an active ester obtained from 1-hydroxysuccinimide is advantageous.
- isocyanate in the system by reacting DPPA in the presence of (II) with a carboxylic acid which can be converted by a transfer reaction to (II) to obtain (I) at once.
- This method is advantageous when the isocyanate derived from the corresponding carboxylic acid is unstable.
- the reaction varies depending on the reactive derivative used, the condensing agent, and the like, but usually, halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform, aromatic hydrocarbons such as benzene, toluene, and xylene, ether, and tetrahydrofuran (Reactions of ethers such as THF), esters such as ethyl acetate, acetonitrile, ⁇ , ⁇ -dimethylformamide (DMF), N, N-dimethylacetoamide, N-methylpyrrolidone and dimethylimidazolidinone (DMI)
- halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ether tetrahydrofuran
- Reactions of ethers such as THF
- esters such as ethy
- an excess of substituted amine (II) may be used, 4.00] 1-7-ene (DBU), 1,5-diazabisik mouth [4.3.0] Non-5-ene 8, 1, 4-diazabisik mouth [2.2.2] octane ( DABC0), 1,4-dimethylpiperazine, sodium hydride (NaH), lithium diisopropylamide (LDA), potassium carbonate, cesium carbonate, sodium carbonate, sodium hydrogencarbonate May be advantageous in smoothly proceeding. It is also possible to accelerate the reaction by adding a phase transfer catalyst such as tetrabutylammonium bromide or a crown ether with 18-crown-6, 15-crown-15. Pyridine or the like can also be used as a solvent.
- a phase transfer catalyst such as tetrabutylammonium bromide or a crown ether with 18-crown-6, 15-crown-15.
- Pyridine or the like can also be used as a solvent.
- the oxygen atom, sulfur atom, nitrogen atom, etc. present in the molecule be bonded to a protecting group.
- a protecting group include Greene and Wuts, Protective Groups in Organic Synthesizer. Protecting groups described in isj 2nd edition can be mentioned, and these can be appropriately used depending on reaction conditions.
- a substituted amine represented by the general formula ⁇ ) or a salt thereof is reacted with carbonic acid or a reactive derivative equivalent to carbonic acid, and then a compound represented by the general formula (IV) is reacted to form a protective group. If present, this is a method for producing the compound (I) of the present invention by removing the protecting group.
- phosgene As reactive derivatives equivalent to carbonic acid, phosgene, phosgene dimer, triphosgene, CDI, N, N-disuccinimidyl carbonyl (DSC), phenyl chlorocarbonate or known equivalents can be used.
- the conditions shown in the first production method can be used.
- the compound of the present invention synthesized according to the above-mentioned production method can be converted to another compound of the present invention by conversion of a functional group or the like using a known reaction.
- Raw material manufacturing method 1
- L represents a functional group which can be substituted by reacting with a halogen such as fluorine, chlorine, bromine, iodine, or an amine such as trifluoromethanesulfonyloxy, benzenesulfonyloxy, and P is benzyl
- Compound ( ⁇ ) used in this production method is prepared by reacting compound (V) with 2,6-transdimethylpiperazine or its ⁇ -substituted derivative (VI), and removing the protecting group by an appropriate reaction. Obtainable.
- optically active (II) can be synthesized by using optically active (VI).
- the optically active (VI) derivatives of ⁇ aryl, benzyl and tert-butoxycarpoel are known.
- (VI) is a racemate or 2,5-transdimethylpiperazine
- optically active (II) can be obtained by performing a condensation reaction in an optically active environment.
- the optically active (II) can be obtained by optically resolving the generated racemate.
- known optically active columns such as optical resolution columns CHIRALCEL 0H-H and CHIRALPAK AD-H of DAICEL can be used.
- optical resolution using an optically active acid is also possible, and the optically active carboxylic acids used in this case include tartaric acid, diparatoluoyltartaric acid, dibenzoyltartaric acid, camphorsulfonic acid, and mandelic acid.
- Organic acids can be used.
- Such an optical resolution method is described in “Organic Synthetic Chemistry Handbook”, edited by Japan Society for Synthetic Organic Chemistry, Maruzen, Tokyo, 1990, p.760.
- (VI) was used in excess, or N-methylmorpholine, trimethylamine, triethylamine, diisopropylethylamine, ⁇ , ⁇ -dimethylaniline, pyridine, DMAP, picoline, lutidine, 8-Pistrimethylaminonaphthalene, organic bases such as DBU, DBN, DABC0, LDA or inorganic bases such as NaH, potassium carbonate, sodium carbonate, calcium carbonate, cesium carbonate, sodium hydrogencarbonate, sodium hydroxide, etc.
- organic bases such as DBU, DBN, DABC0, LDA
- inorganic bases such as NaH, potassium carbonate, sodium carbonate, calcium carbonate, cesium carbonate, sodium hydrogencarbonate, sodium hydroxide, etc.
- the reaction is advantageous in that the reaction proceeds smoothly.
- phase transfer catalyst such as tetrabutylammonium amide and crown ethers such as 18-crown-6, 15-crown-15.
- Pyridine and the like can be used as a solvent.
- organometallic catalyst as a catalyst. For example, Yang, Bryant H .; Buchwald, Stephen L.. Journal of Organometallic ic Chemistry (1999), 576 (1-2), 125 The conditions described in -146 can be used.
- the reaction varies depending on the substrate and conditions used, but is usually halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform, aromatic hydrocarbons such as benzene, toluene, and xylene, and ethers such as ether and tetrahydrofuran.
- halogenated hydrocarbons such as dichloromethane, dichloroethane, and chloroform
- aromatic hydrocarbons such as benzene, toluene, and xylene
- ethers such as ether and tetrahydrofuran.
- Inerts such as acetic acid, ethyl acetate, etc., ethanolic solvents, alcoholic solvents such as methanol, acetonitrile, DMF, N, N-dimethylacetamide, N-methylpyrrolidone, DMI, dimethylsulfoxide, etc.
- organic solvents depending on the reactive derivative, under cooling, under cooling to
- Isocyanate (IX) which is one of the reactive derivatives of (III) used in the first production method, is known from the corresponding carboxylic acid derivatives such as carboxylic acids ( ⁇ ), amides and acid hydrazides. It is preferable to synthesize by utilizing a transfer reaction or the like.
- the compound (in) or its reactive derivative is obtained by reacting the corresponding amine derivative ⁇ ) with phosgene or a phosgene equivalent, and then protecting the nitrogen atom such as various alcohols, phenol derivatives or 1-hydroxysuccinimide.
- Act on ⁇ -hydroxyamine Can be synthesized.
- Known reaction methods such as reacting with various halocarbonate esters such as methylchlorocarbonate and dichloromethane carbonate, or allowing the above-mentioned isocyanate (IX) to act with various alcohols or phenol derivatives, etc. Obtained by the reaction of On the other hand, it is also preferable to synthesize the compound by reacting DSC with the amine derivative (X).
- the compound of the present invention thus produced is isolated and purified as a salt, a hydrate, a solvate, or a crystalline polymorph of the compound as it is.
- the salt of the compound (I) of the present invention can also be produced by subjecting the salt to a conventional salt formation reaction.
- Isolation and purification are performed by applying ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- Various isomers can be stereoselectively synthesized by using appropriate starting compounds, reactants or reaction conditions, or can be separated by utilizing the difference in physical properties between the isomers.
- the optical isomers can be stereochemically selected by selecting appropriate raw materials or by optical resolution of a racemic form (for example, a method of optically resolving a diastereomer with a general optically active base). To pure isomers.
- a preparation containing one or more of the compound of the present invention or a salt thereof as an active ingredient is prepared using a carrier, an excipient, and other additives that are usually used for formulation.
- Administration may be in the form of tablets, pills, capsules, granules, powders, liquids, etc. orally, or injections such as intravenous or intramuscular injection, suppositories, transdermal, etc. Good.
- the dose is determined as appropriate depending on the individual case, taking into account symptoms, age of the subject of administration, gender, etc.In general, for oral administration, for adults 0.01 to 50 mg per day, for parenteral administration, for adults It is about 0.001 to 5 mg per day, and is administered once or in 2 to 4 divided doses.
- the one or more active substances include at least one inert diluent, such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, It is mixed with metasilicic acid and magnesium aluminate.
- the composition may contain an additive other than an inert diluent, for example, a lubricant such as magnesium stearate, a disintegrant such as calcium dalcocholate, and a stabilizer such as lactose.
- Such a solubilizing agent may be contained.
- the tablets or pills may be coated with a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose, or hydroxypropylmethylcellulose phthalate, if necessary.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and commonly used inert diluents such as Contains purified water and ethanol.
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- Patent Document 4 (2R, 5S) obtained by the method described in Reference Example 12-2
- a solution of 25 ml of DMI and 25 ml of acetonitrile containing (11R) -benzyl-1,2,5-dimethylpiperazine lO.Og. 8.17 g of benzonitrile and 31.9 g of cesium carbonate were added, and the mixture was stirred at 120 ° C for 2 days. After adding ethyl acetate to the reaction solution, the mixture was washed with water, and the organic layer was dried over anhydrous sodium sulfate.
- (2R, 5S) 1-14-1 (4-cyano-3-fluorophenyl) -1,2-dimethylpiperazine-11-tert-butyl ruptonate 15.Og was dissolved in 150 ml of dichloromethane, and 30 ml of trifluoroacetic acid was added. The mixture was stirred overnight at room temperature. After distilling off the reaction solution, 1 M hydrochloric acid was added, and the mixture was washed with a black hole form. The aqueous phase was made basic with 5M aqueous sodium hydroxide solution and extracted with chloroform. After the organic layer was dried over anhydrous magnesium sulfate, the solvent was distilled off to obtain 12. Og of the title compound.
- Reference Examples 6-1, 6-2, and 6-4 were also synthesized by the same method as Reference Example 2, and their physical property values corresponded to the physical property values described here.
- 2-fluoroisonicotinic acid 875 mg was suspended in 20 ml of ethyl acetate, 0.76 ml of oxalyl chloride and 01 ml of DMFO were added, and the mixture was stirred at room temperature for 30 minutes. After the solvent was distilled off, ethyl acetate was added again to distill off the solvent. The obtained 2-fluoroisonicotinic acid chloride was dissolved in 20 ml of ethyl acetate, and sodium azide l.Olg was added under ice-cooling, followed by stirring at room temperature for 2 hours.
- the organic layer was washed with saturated aqueous sodium hydrogen carbonate and water, dried over anhydrous sodium sulfate, and the solvent was distilled off. Toluene was added and the solvent was distilled off again to obtain 2-fluoroisonicotinic acid azide.
- the obtained acid azide was heated to reflux in 30 ml of toluene for 30 minutes, converted into 2-fluoro-4-isocyanatopyridine, and then cooled on ice.
- IX pieces of CH0 cells are seeded on a 100-cm diameter cell culture dish, and after 12 to 18 hours, co-precipitated with calcium phosphate, human and oral gene receptor expression plasmid, MMTV-LTR luciferase reporter plasmid (neomycin resistance gene And included a transfection. After 15 hours, the medium was removed, the cells were diluted in several steps, replated, and GENETICIN® (neomycin) was added to the medium to a final concentration of 500 / z g / ml.
- the cells selected by neomycin were detached, and cells that constantly expressed the human androgen receptor expression gene and the MMTV-luciferase reporter gene were isolated and obtained by limiting dilution (CH0 / MMTV stable transformants). ).
- SV40 reporter gene stable transformant was obtained in the same manner as described above. (CHO / SV40 stable transformant). a) Evaluation of transcriptional activation effect on human androgen receptor (agonist effect) CH0 / MMTV stable transformant cells and CH0 / SV40 stable transformant cells were each placed on a 96-well cell culture luminoplate at 2 ⁇ 10 4. The compound of the present invention was added 6 to 8 hours after sowing. Approximately 18 hours after the addition of the compound, the cells were lysed by adding 20 l of a solution containing 1% triton-X and 10% glycerol, 100 l of luciferase substrate solution containing 0.47 luciferin was added, and the luminescence was measured using a luminometer. These were obtained by activation of MMTV-LTR transcription by human androgen receptor and non-specific activation of SV40 promoter transcription. Luciferase activity.
- X (MMTV luciferase-se 'activity) / (SV40 luciferase-se' activity) when the compound of the present invention is added.
- An agonist of the compound of the present invention [Example 3-12]. there were.
- the cells are lysed by adding a solution 201 containing 1% Triton-X and 10 glycerol, and a luciferase substrate solution 1001 containing 0.47 mM luciferin is added. These were determined as the luciferase activities obtained by activating MMTV-LTR transcription by the human androgen receptor and activating nonspecific SV40 promoter transcription.
- X ′ (MMTV Luciferase activity) when the compound of the present invention and 0.3 nM DHT were added simultaneously.
- IC 5 was determined from the concentration of the compound of the present invention at which the inhibition rate calculated by the above method was 50%. I asked.
- rat prostate cytoplasmic fraction One day after orchiectomy, the ventral prostate was removed from a 20-60 week old male Wistar rat. After homogenization, the mixture was centrifuged at 800 X gX for 20 minutes, and the supernatant was further centrifuged at 223,000 X gX for 60 minutes, and the supernatant was collected to obtain a cytoplasmic fraction.
- the cytoplasmic fraction obtained in (1) was adjusted to a protein concentration of 2 mg / ml as a rat androgen receptor solution.
- To the rat androgen receptor solution 400 1 was added 3 H-mibolerone, triamcinoamine acetate, and dimethyl sulfoxide (DMS0) to a final concentration of 1 ⁇ , 1 M, and 4%, respectively, to make the final volume 500 1.
- the compound of the present invention was suspended in a 0.5% methylcellulose solution and orally administered once daily for 15 days to male Wistar rats aged 9 to 10 weeks. Six hours after the final administration, the wet weight of the ventral prostate was measured, and the prostate reducing effect of the compound of the present invention was examined.
- the prostate reducing action of the compound of the present invention was determined by administering the compound of the present invention to a test group, The group to which only the loin was administered was used as a control group to calculate by the following formula.
- Reduction rate (%) 1 0 0 (B-A) /
- Control compound 2 Example 1-8-7 described in Patent Document 4
- the control compound is structurally similar, has clinically sufficient activity, and has no clinically applicable effects such as weight loss. The above two possible compounds were selected.
- Patent Document 4 the compounds having the strongest binding activity, that is, Examples 13-1 and 21 showed a strong prostate reduction effect, but due to problems such as weight loss and agonist action, antiandrogen This was because there was a problem in developing it as a drug and it was not suitable as a control compound.
- the anti-androgenic activity of the compound of the present invention is about 1/2 to about 2 times that of the compound of the present invention in comparison with the control compound, whereas the Was unexpectedly potent, 2 to 10 times.
- the compound of the present invention is a compound having excellent oral activity. Furthermore, since it has excellent oral activity, it has an effect even when administered in a smaller amount than conventional compounds, so that it can be made into a small preparation and the ingestibility can be improved.
- the compound of the present invention is excellent in water solubility, there is no need to devise a formulation such as solubilization.
- the compound of the present invention is useful as a therapeutic agent for diseases such as prostate cancer, prostatic hypertrophy, androgenesis, hirsutism, baldness, acne, seborrhea and the like, in which androgen is an aggravating factor.
- diseases such as prostate cancer, prostatic hypertrophy, androgenesis, hirsutism, baldness, acne, seborrhea and the like, in which androgen is an aggravating factor.
- the compound of the present invention is a strong anti-androgen agent having little effect on blood sex hormones and no weight-loss agonist activity, and is also a compound which is more excellent in oral activity than conventional compounds.
- the compound of the present invention is useful as an agent for treating or preventing prostate cancer, benign prostatic hyperplasia, virilization, hirsutism, baldness, acne, seborrhea and the like.
- the compound represented by the general formula (Ufa) is useful as an intermediate for producing the compound (I) of the present invention.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004521198A JP4449746B2 (ja) | 2002-07-12 | 2003-07-11 | N−フェニル−(2r,5s)ジメチルピペラジン誘導体 |
DK03764179.2T DK1557411T3 (da) | 2002-07-12 | 2003-07-11 | N-phenyl-(2r,5s)-dimethylpiperazin-derivat |
EP03764179A EP1557411B1 (en) | 2002-07-12 | 2003-07-11 | N-phenyl-(2r,5s)dimethylpiperazine derivative |
CA2492138A CA2492138C (en) | 2002-07-12 | 2003-07-11 | N-phenyl-(2r,5s)dimethylpiperazine derivative |
US10/521,119 US7297698B2 (en) | 2002-07-12 | 2003-07-11 | N-phenyl-(2R,5S) dimethylpiperazine derivative |
SI200332218T SI1557411T1 (ja) | 2002-07-12 | 2003-07-11 | |
AU2003248052A AU2003248052A1 (en) | 2002-07-12 | 2003-07-11 | N-phenyl-(2r,5s)dimethylpiperadine derivative |
ES03764179T ES2393333T3 (es) | 2002-07-12 | 2003-07-11 | Derivado de N-fenil-(2R,5S)dimetilpiperazina |
US11/861,327 US7666873B2 (en) | 2002-07-12 | 2007-09-26 | N-phenyl-(2R,5S)dimethylpiperazine derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-203690 | 2002-07-12 | ||
JP2002203690 | 2002-07-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10521119 A-371-Of-International | 2003-07-11 | ||
US11/861,327 Division US7666873B2 (en) | 2002-07-12 | 2007-09-26 | N-phenyl-(2R,5S)dimethylpiperazine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004007471A1 true WO2004007471A1 (ja) | 2004-01-22 |
Family
ID=30112682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008860 WO2004007471A1 (ja) | 2002-07-12 | 2003-07-11 | N−フェニル−(2r,5s)ジメチルピペラジン誘導体 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7297698B2 (ja) |
EP (1) | EP1557411B1 (ja) |
JP (1) | JP4449746B2 (ja) |
AU (1) | AU2003248052A1 (ja) |
CA (1) | CA2492138C (ja) |
CY (1) | CY1113335T1 (ja) |
DK (1) | DK1557411T3 (ja) |
ES (1) | ES2393333T3 (ja) |
PT (1) | PT1557411E (ja) |
SI (1) | SI1557411T1 (ja) |
WO (1) | WO2004007471A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016928A1 (ja) | 2003-08-15 | 2005-02-24 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン誘導体 |
WO2005108399A1 (ja) * | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
JP2006517574A (ja) * | 2003-02-14 | 2006-07-27 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
WO2012053630A1 (ja) | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | 変異アンドロゲン受容体拮抗薬 |
WO2013058361A1 (ja) | 2011-10-21 | 2013-04-25 | アステラス製薬株式会社 | アンドロゲン受容体拮抗化合物の結晶 |
JP2018502070A (ja) * | 2014-12-08 | 2018-01-25 | ドングク ユニバーシティ インダストリー−アカデミック コーポレイション ファウンデーション | 新規な4−(アリール)−N−(2−アルコキシチエノ[3,2−b]ピラジン−3−イル)−ピペラジン−1−カルボキサミド誘導体及びその抗増殖効果 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
TW200628446A (en) * | 2004-12-14 | 2006-08-16 | Takeda Pharmaceuticals Co | Substituted pyrrole derivative |
EP2044029B1 (en) * | 2006-07-14 | 2011-01-26 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
US8268872B2 (en) * | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
MX2010009162A (es) * | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
PE20121438A1 (es) * | 2009-09-24 | 2012-10-26 | Hoffmann La Roche | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a |
CA2788907A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
US9273027B2 (en) * | 2010-02-24 | 2016-03-01 | Research Triangle Institute | Arylpiperazine opioid receptor antagonists |
HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
US8765767B2 (en) * | 2012-03-16 | 2014-07-01 | Bristol-Myers Squibb Company | Positive allosteric modulators of mGluR2 |
WO2016196955A1 (en) * | 2015-06-04 | 2016-12-08 | Drexel University | Inhibitors of RAD52 Recombination Protein and Methods Using Same |
CN105130847A (zh) * | 2015-09-10 | 2015-12-09 | 成都大学 | 一种制备高纯邻甲基苯腈及其衍生物的方法 |
KR20220035276A (ko) | 2016-06-22 | 2022-03-21 | 일립시스 파마 리미티드 | Ar+ 유방암 치료 방법 |
SG11202009388XA (en) | 2018-03-26 | 2020-10-29 | Basf Se | Novel hyperbranched polyesters and their use as wax inhibitor, as pour point depressant, as lubricant or in lubricating oils |
JP2022549222A (ja) * | 2019-09-23 | 2022-11-24 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規尿素およびその使用 |
AU2022333206A1 (en) | 2021-08-27 | 2024-04-11 | Basf Se | Aqueous dispersions of paraffin inhibitors |
WO2023030939A1 (en) | 2021-08-30 | 2023-03-09 | Basf Se | Hyperbranched polyesters modified with branched fatty acids and their use as paraffin inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4981332A (ja) | 1972-11-24 | 1974-08-06 | ||
EP0100172A1 (en) | 1982-07-23 | 1984-02-08 | Imperial Chemical Industries Plc | Amide derivatives |
WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
WO2000017163A1 (fr) | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de cyanophenyle |
JP2001328938A (ja) * | 2000-03-17 | 2001-11-27 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体を有効成分とする医薬 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4694004A (en) * | 1984-07-09 | 1987-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
-
2003
- 2003-07-11 ES ES03764179T patent/ES2393333T3/es not_active Expired - Lifetime
- 2003-07-11 SI SI200332218T patent/SI1557411T1/sl unknown
- 2003-07-11 US US10/521,119 patent/US7297698B2/en active Active
- 2003-07-11 DK DK03764179.2T patent/DK1557411T3/da active
- 2003-07-11 WO PCT/JP2003/008860 patent/WO2004007471A1/ja active Application Filing
- 2003-07-11 JP JP2004521198A patent/JP4449746B2/ja not_active Expired - Fee Related
- 2003-07-11 EP EP03764179A patent/EP1557411B1/en not_active Expired - Lifetime
- 2003-07-11 AU AU2003248052A patent/AU2003248052A1/en not_active Abandoned
- 2003-07-11 PT PT03764179T patent/PT1557411E/pt unknown
- 2003-07-11 CA CA2492138A patent/CA2492138C/en not_active Expired - Fee Related
-
2007
- 2007-09-26 US US11/861,327 patent/US7666873B2/en not_active Expired - Fee Related
-
2012
- 2012-11-19 CY CY20121101108T patent/CY1113335T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4981332A (ja) | 1972-11-24 | 1974-08-06 | ||
EP0100172A1 (en) | 1982-07-23 | 1984-02-08 | Imperial Chemical Industries Plc | Amide derivatives |
WO1995019770A1 (en) | 1994-01-21 | 1995-07-27 | Sepracor, Inc. | Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex |
WO2000017163A1 (fr) | 1998-09-22 | 2000-03-30 | Yamanouchi Pharmaceutical Co., Ltd. | Derives de cyanophenyle |
JP2001328938A (ja) * | 2000-03-17 | 2001-11-27 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体を有効成分とする医薬 |
Non-Patent Citations (4)
Title |
---|
NIHON RINSHO, vol. 56, no. 8, 1998, pages 2124 - 2128 |
PROSTATE, vol. 6, 1996, pages 45 - 51 |
See also references of EP1557411A4 * |
TRENDS IN ENDOCRINOLOGY AND METABOLISM, vol. 9, no. 8, 1998, pages 317 - 324 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006517574A (ja) * | 2003-02-14 | 2006-07-27 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
JP4909068B2 (ja) * | 2003-02-14 | 2012-04-04 | グラクソ グループ リミテッド | カルボキサミド誘導体 |
WO2005016928A1 (ja) | 2003-08-15 | 2005-02-24 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン誘導体 |
US7504412B2 (en) | 2003-08-15 | 2009-03-17 | Banyu Pharmaceuticals, Co., Ltd. | Imidazopyridine derivatives |
WO2005108399A1 (ja) * | 2004-05-10 | 2005-11-17 | Banyu Pharmaceutical Co., Ltd. | イミダゾピリジン化合物 |
WO2012053630A1 (ja) | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | 変異アンドロゲン受容体拮抗薬 |
CN103180309A (zh) * | 2010-10-22 | 2013-06-26 | 安斯泰来制药株式会社 | 突变雄激素受体拮抗剂 |
WO2013058361A1 (ja) | 2011-10-21 | 2013-04-25 | アステラス製薬株式会社 | アンドロゲン受容体拮抗化合物の結晶 |
JP2018502070A (ja) * | 2014-12-08 | 2018-01-25 | ドングク ユニバーシティ インダストリー−アカデミック コーポレイション ファウンデーション | 新規な4−(アリール)−N−(2−アルコキシチエノ[3,2−b]ピラジン−3−イル)−ピペラジン−1−カルボキサミド誘導体及びその抗増殖効果 |
Also Published As
Publication number | Publication date |
---|---|
US20080214543A1 (en) | 2008-09-04 |
EP1557411A1 (en) | 2005-07-27 |
SI1557411T1 (ja) | 2013-01-31 |
CA2492138A1 (en) | 2004-01-22 |
AU2003248052A1 (en) | 2004-02-02 |
EP1557411A4 (en) | 2011-02-23 |
CY1113335T1 (el) | 2016-06-22 |
US7666873B2 (en) | 2010-02-23 |
EP1557411B1 (en) | 2012-10-17 |
JP4449746B2 (ja) | 2010-04-14 |
CA2492138C (en) | 2011-01-11 |
JPWO2004007471A1 (ja) | 2005-11-17 |
US7297698B2 (en) | 2007-11-20 |
US20050261303A1 (en) | 2005-11-24 |
ES2393333T3 (es) | 2012-12-20 |
PT1557411E (pt) | 2012-11-22 |
DK1557411T3 (da) | 2012-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004007471A1 (ja) | N−フェニル−(2r,5s)ジメチルピペラジン誘導体 | |
US6673799B1 (en) | Cyanophenyl derivative | |
WO1998022432A1 (fr) | Derives d'acylanilide a substitution acylamino ou composition comprenant ces derives | |
CA2848824A1 (en) | Azetidine compounds, compositions and their use as inhibitors of soluble epoxide hydrolase | |
IE72101B1 (en) | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile | |
JP2001261657A (ja) | シアノフェニル誘導体 | |
JP2002088073A (ja) | 抗アンドロゲン剤 | |
WO2006028161A1 (ja) | セロトニン5-ht3受容体作動薬 | |
WO2018001332A1 (zh) | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 | |
JP2001328938A (ja) | シアノフェニル誘導体を有効成分とする医薬 | |
WO2017018475A1 (ja) | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 | |
US20120157482A1 (en) | Compounds and methods | |
US20120088809A1 (en) | 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds | |
JP2011508758A (ja) | N−フェニルイミダゾ[1,2−α]ピリジン−2−カルボキサミド誘導体、これらの調製およびこれらの治療用途 | |
JP2021531287A (ja) | Magl阻害剤としての複素環式スピロ化合物 | |
EP0707587B1 (en) | Pharmacologically active enantiomers | |
JP2004514678A (ja) | ベンズイミダゾール誘導体、それらの製造ならびにそれらの治療的適用 | |
JPH11180979A (ja) | 環状アミン誘導体 | |
JPH05331151A (ja) | キノキサリン−2−オン誘導体 | |
WO1995025100A1 (fr) | Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes | |
EP4337656A1 (en) | Substituted heterocyclic compounds | |
CA3202328A1 (en) | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases | |
JPH0827154A (ja) | アザクロマン誘導体及びその用途 | |
WO2010092286A1 (fr) | Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
JP2012517412A (ja) | N−[(6−アザビシクロ[3.2.1]オクト−1−イル)−アリール−メチル]−ベンズアミド誘導体、これらの調製およびこれらの治療的使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004521198 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492138 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003764179 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10521119 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003764179 Country of ref document: EP |